197 related articles for article (PubMed ID: 1948752)
1. [The anticoagulant activity of the plasma ultrafiltrate as a possible criterion of uremic poisoning].
Sukhanov VA; Chuzhinov SV; Koriakov IO; Zlokazov VB
Ter Arkh; 1991; 63(6):68-71. PubMed ID: 1948752
[No Abstract] [Full Text] [Related]
2. [Middle molecules and the problem of endogenous intoxication in critical states of various etiologies].
Vladyka AS; Levitskiĭ ER; Poddubnaia LP; Gabriélian NI
Anesteziol Reanimatol; 1987; (2):37-42. PubMed ID: 3300433
[No Abstract] [Full Text] [Related]
3. [Detection of uremic peaks by high performance liquid chromatography and their behavior].
Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Uehara Y
Nihon Jinzo Gakkai Shi; 1986 Aug; 28(8):1101-10. PubMed ID: 3807043
[No Abstract] [Full Text] [Related]
4. Middle molecule accumulation in uremia: an "extra uremic factor".
Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
[TBL] [Abstract][Full Text] [Related]
5. [Nature of the organic lesions in uremic poisoning].
Beliakov NA; Levanovich VV; Solomennikov AV; Malakhova MIa; Pirgach NV
Vestn Khir Im I I Grek; 1986 Oct; 137(10):122-7. PubMed ID: 3798647
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
Ringoir SM; van Landschoot N; de Smet R
Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
[TBL] [Abstract][Full Text] [Related]
7. A rapid and sensitive method for simultaneous determination of eight protein-bound uremic toxins in human serum by UHPLC-MS/MS: application in assessing peritoneal dialysis.
Wang Z; Jiang H; Chen X; Song X; Xu F; Chen F; Mao Z; Gao S; Chen W
J Pharm Biomed Anal; 2020 Jul; 186():113312. PubMed ID: 32361090
[TBL] [Abstract][Full Text] [Related]
8. Dialysis therapy: 'think differently'.
Perrone B
Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
[No Abstract] [Full Text] [Related]
9. [Effect of an oral sorbent (AST-120) on the clinical course of uremic peak 2a in chronic renal failure].
Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Ono S
Nihon Jinzo Gakkai Shi; 1987 Aug; 29(8):1003-11. PubMed ID: 3694879
[No Abstract] [Full Text] [Related]
10. [Examination of lymphokines in patients with hemodialysis (author's transl)].
Löcsey L; Kálmán K; Hauck M; Kakuk G
Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
[TBL] [Abstract][Full Text] [Related]
11. Serum middle molecules in uremia.
Buzio C; Manari A; Calderini C; Montagna G; Migone L
Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
[No Abstract] [Full Text] [Related]
12. Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma.
Faioni EM; Franchi F; Krachmalnicoff A; Valsecchi C; Viganò GL; Remuzzi G; Mannucci PM
Thromb Haemost; 1991 Oct; 66(4):420-5. PubMed ID: 1796390
[TBL] [Abstract][Full Text] [Related]
13. [Hemosorption as a treatment method for uremic complications].
Pilotovich VS; Ostapenko VA; Shilaĭ LM; Kirkovskiĭ VV; Nikolaĭchik VV
Klin Med (Mosk); 1982 Apr; 60(4):77-80. PubMed ID: 7098397
[No Abstract] [Full Text] [Related]
14. Middle molecules in renal failure.
Leber HW; Goubeaud G; Spiegelhalter R
Ann Clin Biochem; 1979 Nov; 16(6):389-95. PubMed ID: 539797
[No Abstract] [Full Text] [Related]
15. Uremic toxins.
Ringoir S; Schoots A; Vanholder R
Kidney Int Suppl; 1988 Mar; 24():S4-9. PubMed ID: 3283412
[No Abstract] [Full Text] [Related]
16. [Dialysis treatment of chronic kidney insufficiency in the uremic phase. Indications and limitations].
Garini G; Savazzi G; Arisi L
Recenti Prog Med; 1986 Sep; 77(9):440-3. PubMed ID: 3797795
[No Abstract] [Full Text] [Related]
17. Analysis of plasma middle molecular fraction in uremic patients.
Kovalishin YaF
Biomater Artif Cells Artif Organs; 1987; 15(3):605-10. PubMed ID: 3440134
[TBL] [Abstract][Full Text] [Related]
18. [On-line HFR and removal of uremic toxins inducing the loss of phospholipidic asymmetry of the erythrocyte membrane].
Sirolli V; Cappelli P; Amoroso L; Di Liberato L; Muscianese P; Santarelli P; Del Rosso G; Bonomini M
G Ital Nefrol; 2004; 21 Suppl 30():S208-11. PubMed ID: 15750987
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics and evolution of uremic pleural effusion].
Agustí C; Campistol JM; Xaubet A; Picado C; Cases A; Revert L; Agustí-Vidal A
Med Clin (Barc); 1988 Apr; 90(17):693-5. PubMed ID: 3412039
[No Abstract] [Full Text] [Related]
20. Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment.
Válek A; Dzúrik R; Spustová V; Válková D
Artif Organs; 1981; 4 Suppl():173-6. PubMed ID: 7295088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
